Real-World Studies
Real-World CML Outcomes in Safety-Net Health Systems
Zheng et alCancer Medicine
In a retrospective chart review evaluating real-world tyrosine kinase inhibitor (TKI) treatment patterns and outcomes among 108 adult patients with chronic myeloid leukemia (CML) at Los Angeles County safety-net hospitals between 2015 and 2024, researchers observed less favorable clinical outcomes despite a younger median age at diagnosis. While contemporary 5-year overall survival in CML generally exceeds 90% with modern TKI regimens, significant disparities persist in underserved patient populations.
The cohort was predominantly Hispanic (58.3%) and lower-income, with 59.2% residing in zip codes with household incomes below the national average. The median age at diagnosis was 46 years. Comorbidities were documented in 82.4% of patients at baseline, most frequently elevated body mass index (67.5%), hypertension (28.7%), and diabetes mellitus (20.4%). Based on European Treatment and Outcome Study (EUTOS) risk stratification, 55.6% of patients were low risk and 11.1% were high risk.
Initial systemic management consisted primarily of imatinib (64.8%), followed by dasatinib (31.5%). First-line efficacy and tolerability were suboptimal: major molecular response (MMR; >3-log reduction) was reached by 44.4% of patients, and 43.5% discontinued first-line therapy because of drug intolerance. Consequently, 56.5% of patients advanced to a second line of therapy, and 27.0% ultimately required a third line. The authors noted that compared to previously published cohorts, these underserved patients experienced lower rates of first-line MMR, higher rates of treatment-limiting toxicity, and increased utilization of subsequent lines of therapy.
Key Takeaways
- In an underserved safety-net cohort, first-line tyrosine kinase inhibitor therapy yielded a major molecular response rate of only 44.4%, with 43.5% of patients discontinuing initial treatment due to medication intolerance.
- Subsequent treatment switching was common, with 56.5% of patients progressing to a second line of therapy and 27.0% requiring a third line.
Read the original sourceCancer Medicine
